Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Expenses (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Accumulated Expenses for 3 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 56.68% year-over-year to $7.6 million; the TTM value through Dec 2025 reached $7.6 million, up 56.68%, while the annual FY2025 figure was $7.6 million, 56.68% up from the prior year.
  • Accumulated Expenses hit $7.6 million in Q4 2025 for Artiva Biotherapeutics, up from $5.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $8.3 million in Q3 2024 and bottomed at $2.5 million in Q1 2025.
  • Average Accumulated Expenses over 3 years is $5.4 million, with a median of $5.2 million recorded in 2024.
  • On a YoY basis, Accumulated Expenses climbed as much as 56.68% in 2025 and fell as far as 41.26% in 2025.
  • Artiva Biotherapeutics' Accumulated Expenses stood at $4.0 million in 2023, then grew by 19.37% to $4.8 million in 2024, then surged by 56.68% to $7.6 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $7.6 million, $5.6 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.